Released: Friday 8th April 2022

Medannex’s first-in-class agent shows significant activity against clinically challenging cancers

Medannex Ltd (Edinburgh) today announced new data for their first-in-class monoclonal antibody, MDX-124, showing significant activity in preclinical models of various cancers with high unmet medical need. The results were released at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, USA on 8 April 2022.

By targeting annexin-A1, MDX-124 significantly decreased cancer cell migration in models of pancreatic, prostate, colorectal, lung and triple-negative breast cancer. MDX-124 also reduced the expression of several other key proteins involved in cancer cell migration, invasion and metastasis.

Furthermore, in an in-vivo model of prostate cancer, MDX-124 significantly decreased tumour growth by 52%. Prostate cancer is the second most commonly occurring cancer in men, with more than 47,500 new cases every year in the UK alone.

The new data build on Medannex’s other recent presentations at international symposia demonstrating MDX-124’s multifaceted anti-cancer activity as a single agent and significant synergy with widely-used chemotherapies that form the backbone of many cancer treatment regimens.

Professor Daniel Palmer of the University of Liverpool’s Department of Molecular and Clinical Cancer Medicine, the Chief Investigator for the First-in-Human study of MDX-124, commented: "These non-clinical results showing the significant anti-tumour effect of MDX-124 in various cancers are a strong platform for the upcoming clinical study, recruitment for which we will begin in a matter of weeks. We are excited about the potential of this agent as a new approach to cancer treatment.’

Medannex CEO Ian Abercrombie said: ‘we are delighted to be bringing MDX-124, the first in a new class of medicine, to the clinic and to take a fresh approach to cancer treatment. Generating the first clinical data with our novel agent will be the culmination of a huge effort by the Medannex team and our scientific collaborators and the gateway to an exciting future for the company.’

The new data were generated by Medannex in collaboration with the University of Edinburgh, ARU (Cambridge) and Brighton & Sussex Medical School, and can be viewed in full here: https://medannex.org/wp-content/uploads/2022/04/220321-AACR-2022-ePoster-5294-FINAL.pdf

About Medannex Ltd: Medannex is a privately-owned biopharmaceutical company registered in Scotland,
with headquarters in Edinburgh. The company is developing novel treatments to improve the lives of people
suffering from cancers, autoimmune diseases and other conditions, and is currently engaging with investors regarding an ongoing financing round: https://medannex.org

About MDX-124: MDX-124 is a humanised monoclonal antibody, and the first agent to specifically target and inhibit annexin-A1, a protein known to play a key role in the development of cancers, autoimmune diseases and other conditions. Medannex will generate initial clinical data in 2022 from a First-in-Human study evaluating MDX-124 in patients with locally advanced, unresectable or metastatic solid malignancies.

- ENDS -

Medannex Ltd enquiries – email jamesingham@medannex.org